Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study

Payam Tabarsi, Parvaneh Baghaei, Sara Jalali, Parisa Farnia, Ehsan Chitsaz, Mehdi Mirsaeidi, Mehdi Kazempour, Davoud Mansouri, Mohammad Masjedi, Ali Velayati

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The clinical relevance of second-line drug susceptibility test (DST) results with respect to treatment outcome is unknown in non-XDR MDR patients. This study was carried out in the sole national referral centre for TB in Iran between 2002 and 2006. Multidrug-resistant tuberculosis (MDR-TB) patients who had DST to second-line drugs were included. For all MDR-TB patients the standard second-line regimen was initiated. Outcome of treatment based on DST to second-line drugs was analysed. 53 patients were included. DST for second-line drugs was available for 40 patients. Seven patients returned to Afghanistan during treatment. Among the remainder, 13 (30.4%) cases were Iranian. Mean age was 40.8 + 19.7 y. The relatively small sample size imposes some limitations on this study. However, in this study, there was no difference in resistance to second-line drugs by nationality. No significant correlation was seen between resistance to second-line drugs and outcome of treatment. In conclusion, the treatment outcome according to WHO definitions was appropriate in the study population by the use of standardized treatment regimens. Follow-up studies on a long-term basis are however needed in order to detect possible relapses.

Original languageEnglish (US)
Pages (from-to)10-13
Number of pages4
JournalScandinavian Journal of Infectious Diseases
Volume41
Issue number1
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Multidrug-Resistant Tuberculosis
Pharmaceutical Preparations
Therapeutics
Clinical Studies
Afghanistan
Iran
Ethnic Groups
Sample Size
Referral and Consultation
Recurrence

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Microbiology(all)
  • Infectious Diseases

Cite this

Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study. / Tabarsi, Payam; Baghaei, Parvaneh; Jalali, Sara; Farnia, Parisa; Chitsaz, Ehsan; Mirsaeidi, Mehdi; Kazempour, Mehdi; Mansouri, Davoud; Masjedi, Mohammad; Velayati, Ali.

In: Scandinavian Journal of Infectious Diseases, Vol. 41, No. 1, 2009, p. 10-13.

Research output: Contribution to journalArticle

Tabarsi, P, Baghaei, P, Jalali, S, Farnia, P, Chitsaz, E, Mirsaeidi, M, Kazempour, M, Mansouri, D, Masjedi, M & Velayati, A 2009, 'Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study', Scandinavian Journal of Infectious Diseases, vol. 41, no. 1, pp. 10-13. https://doi.org/10.1080/00365540802298079
Tabarsi, Payam ; Baghaei, Parvaneh ; Jalali, Sara ; Farnia, Parisa ; Chitsaz, Ehsan ; Mirsaeidi, Mehdi ; Kazempour, Mehdi ; Mansouri, Davoud ; Masjedi, Mohammad ; Velayati, Ali. / Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study. In: Scandinavian Journal of Infectious Diseases. 2009 ; Vol. 41, No. 1. pp. 10-13.
@article{48afa522464f41cf98fb82bc0f41a491,
title = "Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study",
abstract = "The clinical relevance of second-line drug susceptibility test (DST) results with respect to treatment outcome is unknown in non-XDR MDR patients. This study was carried out in the sole national referral centre for TB in Iran between 2002 and 2006. Multidrug-resistant tuberculosis (MDR-TB) patients who had DST to second-line drugs were included. For all MDR-TB patients the standard second-line regimen was initiated. Outcome of treatment based on DST to second-line drugs was analysed. 53 patients were included. DST for second-line drugs was available for 40 patients. Seven patients returned to Afghanistan during treatment. Among the remainder, 13 (30.4{\%}) cases were Iranian. Mean age was 40.8 + 19.7 y. The relatively small sample size imposes some limitations on this study. However, in this study, there was no difference in resistance to second-line drugs by nationality. No significant correlation was seen between resistance to second-line drugs and outcome of treatment. In conclusion, the treatment outcome according to WHO definitions was appropriate in the study population by the use of standardized treatment regimens. Follow-up studies on a long-term basis are however needed in order to detect possible relapses.",
author = "Payam Tabarsi and Parvaneh Baghaei and Sara Jalali and Parisa Farnia and Ehsan Chitsaz and Mehdi Mirsaeidi and Mehdi Kazempour and Davoud Mansouri and Mohammad Masjedi and Ali Velayati",
year = "2009",
doi = "10.1080/00365540802298079",
language = "English (US)",
volume = "41",
pages = "10--13",
journal = "Infectious Diseases",
issn = "2374-4235",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study

AU - Tabarsi, Payam

AU - Baghaei, Parvaneh

AU - Jalali, Sara

AU - Farnia, Parisa

AU - Chitsaz, Ehsan

AU - Mirsaeidi, Mehdi

AU - Kazempour, Mehdi

AU - Mansouri, Davoud

AU - Masjedi, Mohammad

AU - Velayati, Ali

PY - 2009

Y1 - 2009

N2 - The clinical relevance of second-line drug susceptibility test (DST) results with respect to treatment outcome is unknown in non-XDR MDR patients. This study was carried out in the sole national referral centre for TB in Iran between 2002 and 2006. Multidrug-resistant tuberculosis (MDR-TB) patients who had DST to second-line drugs were included. For all MDR-TB patients the standard second-line regimen was initiated. Outcome of treatment based on DST to second-line drugs was analysed. 53 patients were included. DST for second-line drugs was available for 40 patients. Seven patients returned to Afghanistan during treatment. Among the remainder, 13 (30.4%) cases were Iranian. Mean age was 40.8 + 19.7 y. The relatively small sample size imposes some limitations on this study. However, in this study, there was no difference in resistance to second-line drugs by nationality. No significant correlation was seen between resistance to second-line drugs and outcome of treatment. In conclusion, the treatment outcome according to WHO definitions was appropriate in the study population by the use of standardized treatment regimens. Follow-up studies on a long-term basis are however needed in order to detect possible relapses.

AB - The clinical relevance of second-line drug susceptibility test (DST) results with respect to treatment outcome is unknown in non-XDR MDR patients. This study was carried out in the sole national referral centre for TB in Iran between 2002 and 2006. Multidrug-resistant tuberculosis (MDR-TB) patients who had DST to second-line drugs were included. For all MDR-TB patients the standard second-line regimen was initiated. Outcome of treatment based on DST to second-line drugs was analysed. 53 patients were included. DST for second-line drugs was available for 40 patients. Seven patients returned to Afghanistan during treatment. Among the remainder, 13 (30.4%) cases were Iranian. Mean age was 40.8 + 19.7 y. The relatively small sample size imposes some limitations on this study. However, in this study, there was no difference in resistance to second-line drugs by nationality. No significant correlation was seen between resistance to second-line drugs and outcome of treatment. In conclusion, the treatment outcome according to WHO definitions was appropriate in the study population by the use of standardized treatment regimens. Follow-up studies on a long-term basis are however needed in order to detect possible relapses.

UR - http://www.scopus.com/inward/record.url?scp=58049211945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58049211945&partnerID=8YFLogxK

U2 - 10.1080/00365540802298079

DO - 10.1080/00365540802298079

M3 - Article

C2 - 19037820

AN - SCOPUS:58049211945

VL - 41

SP - 10

EP - 13

JO - Infectious Diseases

JF - Infectious Diseases

SN - 2374-4235

IS - 1

ER -